India's Stance On IPRs, Pharma in FTA Will Fosters Growth Of Generic Drug Sector

India's Stance On IPRs, Pharma in FTA Will Fosters Growth Of Generic Drug Sector: GTRI India's position on intellectual property rights (IPRs) and pharmaceutical issues in proposed trade agreements strikes a balance between fostering innovation and addressing public health needs. This stance ensures the availability of affordable medicines and supports the growth of the generic medicine industry, according to a report by the Global Trade Research Initiative (GTRI). By resisting pressures from developed nations regarding concepts like 'data exclusivity' and 'patent linkage' in free trade agreements (FTAs), India facilitates greater market access for generic drug manufacturers, leading to a significant reduction in the cost of life-saving medications. "India's approach underscores a commitment to balancing innovation with public health needs, adopting a flexible interpretation of TRIPS to align with its developmental goals, and preventing the establishment of unfair monopolies, especially in the pharmaceutical sector," the GTRI paper said. [Read more](/dHJpc3RyYW1iYWxkd2luODVAZ21haWwuY29t/aHR0cHMlM0ElMkYlMkZuZXdzLmFicGxpdmUuY29tJTJGYnVzaW5lc3MlMkZpbmRpYS1zLXN0YW5jZS1vbi1pcHJzLXBoYXJtYS1pbi1mdGEtd2lsbC1mb3N0ZXJzLWdyb3d0aC1vZi1nZW5lcmljLWRydWctc2VjdG9yLWd0cmktMTY2NDk1OA==) Â We respect your privacy. If you are not interested in receiving further emails, please Click [here](/dHJpc3RyYW1iYWxkd2luODVAZ21haWwuY29t)